SGHT News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

SG

Mkt Cap

$457.1M

Volume

253.22K

Next Earnings

November 5th

Loading chart

SG

SGHTSight Sciences, Inc. Common Stock

SGHT

Pay with—

Available Balance0.00

SG

Mkt Cap

$484.8M

Volume

253.22K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

UnitedHealthcare Adds Sight Sciences OMNI System To Covered Glaucoma Surgery ProceduresUnitedHealthcare updated its Glaucoma Surgical Treatments policy to cover OMNI Surgical System procedures for treating mild to moderate open-angle glaucoma, effective October 1, 2025, covering approximately 30 million lives.Benzinga · Sep 9, 2025

Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye DiseaseA cost-utility analysis revealed that TearCare® System offers cost savings and better health utility compared to cyclosporine 0.05% for treating meibomian gland disease-associated dry eye disease, with $903 annual per-patient savings.GlobeNewswire Inc. · Jul 30, 2025

Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye DiseaseSight Sciences published 24-month results of the SAHARA clinical trial demonstrating the durability of the TearCare® System for treating dry eye disease, showing statistically significant improvements in patient symptoms and eye health metrics through two annual treatments.GlobeNewswire Inc. · Jul 29, 2025

Dry Eye Treatment Devices Market Poised to Attain Valuation of US$ 898.78 Million By 2033 | Pharmacological Synergy Driving Demand for Advanced Dry Eye Treatment Devices Says Astute AnalyticaThe global dry eye treatment devices market is expected to reach $898.78 million by 2033, driven by the increasing prevalence of dry eye disease and the development of innovative treatment options. The market is seeing a shift towards more sophisticated devices that offer targeted therapies, such as the LipiFlow System and iLux Device for treating meibomian gland dysfunction, and the trueTear intranasal neurostimulation device for stimulating tear production.GlobeNewswire Inc. · Feb 10, 2025

Sight Sciences to Report Second Quarter Financial Results on August 1, 2024 - GlobeNewswireSight Sciences, Inc. (Nasdaq: SGHT) announced that it will report its financial results for the second quarter of 2024 on August 1, 2024. The company will host a conference call to discuss the results.GlobeNewswire Inc. · Jul 18, 2024

Sight Sciences CFO Alison Bauerlein sells over $65k in company stock By Investing.com - Investing.comSight Sciences CFO Alison Bauerlein sold over $65,000 worth of company stock to cover tax liabilities from vesting of restricted stock units. The company has reported positive developments in its trials and modest revenue growth, but also faces challenges with profitability.Investing.com · Jul 4, 2024

Sight Sciences Announces the Release of its First Sustainability ReportThe Sustainability Report provides data for 2021 through 2023 on the Company’s environmental, social, and governance initiatives The Sustainability Report provides data for 2021 through 2023 on the Company’s environmental, social, and governance initiativesGlobeNewswire Inc. · Jun 10, 2024

Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from RestasisPatients treated with a single interventional eyelid procedure enabled by TearCare® technology after receiving Restasis® for the first six months of the trial realized clinically meaningful improvements in the signs and symptoms of dry eye disease through month twelve. Patients treated with a single interventional eyelid procedure enabled by TearCare® technology after receiving Restasis® for the first six months of the trial realized clinically meaningful improvements in the signs and symptoms of dry eye disease through month twelve.GlobeNewswire Inc. · May 28, 2024

Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced GlaucomaThe analysis published in Clinical Ophthalmology suggests that OMNI was as effective at lowering IOP and reducing medication usage in advanced glaucoma as it was in mild and moderate glaucoma. The analysis published in Clinical Ophthalmology suggests that OMNI was as effective at lowering IOP and reducing medication usage in advanced glaucoma as it was in mild and moderate glaucoma.GlobeNewswire Inc. · May 28, 2024

Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue EstimatesSight Sciences (SGHT) delivered earnings and revenue surprises of -13.79% and 5.06%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · May 2, 2024

to start trading

SG

SGHTSight Sciences, Inc. Common Stock

SGHT

Pay with—

Available Balance0.00

Your PositionYou don't own any SGHT yet.

Related Tickers

Earnings